New treatments for psoriasis

New England Journal of Medicine

Volumn 345, Issue 4, 2001, Pages 284-287

  Granstein, R D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CD2 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HU 1124; HYBRID PROTEIN; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; METHOTREXATE; METHOXSALEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG MECHANISM; EDITORIAL; EFFECTOR CELL; HUMAN; INFLAMMATION; KERATINOCYTE; MEMORY CELL; PRIORITY JOURNAL; PSORIASIS; PUVA; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD45; HUMANS; LYMPHOCYTE COUNT; PSORIASIS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0035954658     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107263450410     Document Type: Editorial

References (14)

1. Treatment of psoriasis
2. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation
3. Skin CD4+ T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis
4. Bacterial superantigens and inflammatory skin diseases
5. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
6. Dermal injection of immunocytes induces psoriasis
7. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis
8. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
9. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
10. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
11. TNF blockade in the treatment of rheumatoid arthritis: Infliximab versus etanercept
12. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
13. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial